IDEAYA Biosciences stock has delivered a 61.0% return over the past five years, yet the current valuation checks and market multiples suggest investors are paying up for that performance rather than seeing an obvious bargain.

• A 61.0% five year return highlights that IDEAYA Biosciences has already rewarded patient shareholders, which can raise the bar for future returns at today’s price.
• Progress on IDEAYA Biosciences' oncology pipeline, including late stage and earlier stage programs, may support expectations for future revenue, while the execution and clinical risk around those same programs can still weigh on what investors should be willing to pay.
• The stock earns a mixed valuation profile, scoring 3 out of 6 checks. This points to neither a clear bargain nor a clearly stretched price on the broader measures.

The stock's next move may depend on whether IDEAYA Biosciences' current price already reflects the progress in its pipeline and financial position, or if the recent gains still leave room for further upside.

Has IDEAYA Biosciences Run Too Far on Sales?

P/S is often the cleaner yardstick for a biotech like IDEAYA Biosciences where earnings are not yet a reliable anchor. IDEAYA trades on a P/S of 14.9x, which is above the Biotechs industry average of 11.5x and sits at about half the peer group average of 29.2x. That places the stock in the upper bracket of the sector on sales, although not at the most extreme end seen among high expectation biotech peers.

The fair P/S ratio implied by the model is 4.3x, which is far below the current 14.9x. Given how heavily the model penalises current losses and risk, that gap looks more like a warning that IDEAYA screens expensive on this framework than a precise target level. Despite the recent progress in IDEAYA Biosciences' oncology pipeline and business updates, the present P/S still assumes a lot of value for future revenue relative to what the model would typically assign.

On this P/S yardstick, IDEAYA Biosciences stock currently screens as overvalued on this measure.

The IDEAYA Biosciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for IDEAYA Biosciences provide a clear bridge from the valuation puzzle above to the specific assumptions that would need to hold for IDEAYA Biosciences' stock to be worth materially more or less than today’s price. Each narrative links its numbers to a concrete view of how growth, margins and risks might evolve, so you can revisit those views as fresh information becomes available on the Community page.

You can add your voice to the IDEAYA Biosciences story by sharing a Narrative that sets out a number driven view on whether milestones like the OptimUM-02 trial result, the IDE892 program and the current cash runway support today’s valuation. Put your case on record and see how it stacks up as new clinical and financial updates emerge.

Do you think there's more to the story for IDEAYA Biosciences? Head over to our Community to see what others are saying!

The Bottom Line

For IDEAYA Biosciences, the current market multiples point to an overvalued stock on the P/S measure, especially given the wide gap to the fair ratio implied by the model. That does not rule out further gains, but it means recent optimism already prices in a lot of future success. The crux for investors is whether IDEAYA Biosciences can deliver clinical and commercial progress that keeps justifying a premium sales multiple, or whether expectations cool and the valuation settles closer to more typical biotech levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.